41.96 -0.13 (-0.30%)
After hours: 4:18PM EDT
|Bid||42.09 x 900|
|Ask||47.91 x 2200|
|Day's Range||41.69 - 42.19|
|52 Week Range||26.10 - 44.47|
|Beta (3Y Monthly)||1.72|
|PE Ratio (TTM)||36.01|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||0.16 (0.42%)|
|1y Target Est||43.18|
Bruker Corp NASDAQ/NGS:BRKRView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for BRKR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BRKR. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BRKR had net inflows of $568 million over the last one-month. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
MONTREAL, May 13, 2019 /PRNewswire/ -- At the Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM), Bruker today announced an agreement to develop the world's first 18 Tesla 11 cm bore, preclinical ultra-high field (UHF) magnetic resonance imaging (MRI) system and its clinical research applications in collaboration with the Champalimaud Foundation. This novel and unique system is expected to enable Champalimaud researchers to advance translational cancer and neuroscience research with UHF MRI and magnetic resonance spectroscopic imaging.
BILERICA, Mass., May 10, 2019 /PRNewswire/ -- Bruker Corporation (BRKR) today announced that on May 9, 2019, its Board of Directors approved a new share repurchase authorization for the purchase of up to $300 million of the Company's common stock over a two-year period commencing May 14, 2019. Under this authorization, the Company may repurchase its common stock from time to time, in amounts, at prices, and at such times as the Company deems appropriate, subject to market conditions, legal requirements and other considerations. The Company's repurchases may be executed using open market purchases, privately negotiated purchases or other transactions, including transactions that may be effected pursuant to trading plans intended to qualify under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, during the period from May 14, 2019 to May 13, 2021.
Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.
Bruker (BRKR) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we will run through one way of estimating the intrinsic value of Bruker Corporation (NASDAQ:BRK...
Bruker (BRKR) delivered earnings and revenue surprises of 16.67% and 1.45%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Billerica, Massachusetts-based company said it had profit of 20 cents. Earnings, adjusted for one-time gains and costs, came to 28 cents per share. The results surpassed Wall ...
- Q1 2019 revenue growth of 6.9% year-over-year (yoy), organic revenue growth of 5.5% yoy; - Q1 2019 GAAP EPS of $0.20 ; Q1 2019 non-GAAP EPS of $0.28 , up 16.7% yoy; - Q1 2019 GAAP operating margin of ...
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BILLERICA, Mass. , April 23, 2019 /PRNewswire/ -- Bruker (NASDAQ: BRKR) today announced it will report first quarter 2019 financial results on Thursday May 2, 2019 , after the market closes. The Company ...
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Bruker Corporation (NASDAQ:BRKR) with a market-capitalization of US$6.2b, rarely draw their attention. However, history shows that overl...
- Reference library expansion for broader species identification by MALDI Biotyper (MBT) - Increased speed for high-throughput projects by multi-threading MBT HT software (RUO) - Increased microbial ID ...